Ontology highlight
ABSTRACT: Purpose
To characterize the safety, pharmacodynamics, and pharmacokinetics (PK) of vericiguat in healthy males.Methods
Six phase I studies were conducted in European, Chinese, and Japanese males. Subjects received oral vericiguat as a single dose (0.5-15.0 mg solution [for first-in-human study] or 1.25-10.0 mg immediate release [IR tablets]) or multiple doses (1.25-10.0 mg IR tablets once daily [QD] or 5.0 mg IR tablets twice daily for 7 consecutive days). Bioavailability and food effects on vericiguat PK (IR tablets) were also studied in European subjects.Results
Overall, 255 of 265 randomized subjects completed their respective studies. There were no deaths or serious adverse events. Vericiguat was generally well tolerated at doses ≤ 10.0 mg. In the first-in-human
SUBMITTER: Boettcher M
PROVIDER: S-EPMC7935833 | biostudies-literature | 2021 Apr
REPOSITORIES: biostudies-literature